bluebird bio Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of bluebird bio Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023 inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 28, 2024.

If you purchased bluebird common stock and would like to join the action, please click “Join This Class Action.”

Class Period:April 24, 2023 through December 8, 2023


33 Days
If you purchased bluebird common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants made false and/or misleading statements. Specifically, defendants created the false impression that:

  • bluebird could obtain Federal Drug Administration (“FDA”) approval for lovo-cel, gene therapy for sickle cell patients, without any black box warnings for haematological malignancies;
  • bluebird would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen bluebird’s financial position for the lovo-cel launch;
  • as a result, bluebird had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and
  • therefore, bluebird’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: bluebird bio Inc.
Stock Symbol: BLUE
Class Period: April 24, 2023 through December 8, 2023
Court: United States District Court for the District of Massachusetts

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top